Nkarta upgraded at Raymond James on valuation

seekingalpha08-14

Nkarta (NASDAQ:NKTX) shares spiked in the premarket Wednesday after Raymond James upgraded the cell therapy developer to Strong Buy from Outperform, citing a compelling valuation setup following the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2459173614?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg","is_english":true,"pubTime":"2024-08-14 20:24","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2459173614","market":"nz","top_or_hot":-1,"title":"Nkarta upgraded at Raymond James on valuation","media":"seekingalpha","content":"<div>\n<p>Nkarta (NASDAQ:NKTX) shares spiked in the premarket Wednesday after Raymond James upgraded the cell therapy developer to Strong Buy from Outperform, citing a compelling valuation setup following the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4139720-nkarta-stock-upgraded-raymond-james\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nkarta upgraded at Raymond James on valuation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNkarta upgraded at Raymond James on valuation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-14 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4139720-nkarta-stock-upgraded-raymond-james><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nkarta (NASDAQ:NKTX) shares spiked in the premarket Wednesday after Raymond James upgraded the cell therapy developer to Strong Buy from Outperform, citing a compelling valuation setup following the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4139720-nkarta-stock-upgraded-raymond-james\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NKTX","symbol_name":"Nkarta","start_time":0,"source_url":"https://seekingalpha.com/news/4139720-nkarta-stock-upgraded-raymond-james","article_id":"2459173614","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2459173614","pubTimestamp":1723638261,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Nkarta  shares spiked in the premarket Wednesday after Raymond James upgraded the cell therapy developer to Strong Buy from Outperform, citing a compelling valuation setup following the company’s quarterly results. With its Q2 2024 financials on Tuesday, the California-based biotech indicated a cash runway into late 2027, which, according to Ray Jay analyst Laura Prendergast, will help the company navigate “numerous de-risking catalysts.” Additionally, the analyst pointed out that Nkarta  is trading below cash, and investors have yet to appreciate its lead product candidate, NKX019, an NK cell therapy in clinical trials for autoimmune conditions. Prendergast pointed out that NK cell therapy has multiple advantages compared to T cell therapy, including those related to safety and administration. Those features could give NKTX an “edge for maneuvering the enrollment headwinds the space is facing,” the analyst wrote, keeping her $16 target on the stock unchanged.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"NKTX":"Nkarta","RJF":"瑞杰金融"},"translate_title":"雷蒙德·詹姆斯(Raymond James)上调Nkarta估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTX":1,"RJF":1},"content_text":"Nkarta (NASDAQ:NKTX) shares spiked in the premarket Wednesday after Raymond James upgraded the cell therapy developer to Strong Buy from Outperform, citing a compelling valuation setup following the company’s quarterly results. With its Q2 2024 financials on Tuesday, the California-based biotech indicated a cash runway into late 2027, which, according to Ray Jay analyst Laura Prendergast, will help the company navigate “numerous de-risking catalysts.” Additionally, the analyst pointed out that Nkarta (NKTX) is trading below cash, and investors have yet to appreciate its lead product candidate, NKX019, an NK cell therapy in clinical trials for autoimmune conditions. Prendergast pointed out that NK cell therapy has multiple advantages compared to T cell therapy, including those related to safety and administration. Those features could give NKTX an “edge for maneuvering the enrollment headwinds the space is facing,” the analyst wrote, keeping her $16 target on the stock unchanged.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2459173614"}